AstraZeneca, Novartis, Pfizer and Teva join new Lhasa Limited data sharing initiative to better understand mutagenic potential of complex nitrosamines
09 March 2022
We are delighted to announce the launch of our new complex nitrosamine data sharing initiative. The project currently holds 4 respected members within the pharmaceutical industry: AstraZeneca, Novartis, Pfizer and Teva, with 5 additional pharmaceutical companies in the process of joining.
Lhasa Limited releases skin sensitisation defined approach ITSv1 1.0 - providing hazard and potency skin sensitisation predictions without the use of animal tests
14 February 2022
Lhasa’s new web application ‘skin sensitisation defined approach ITSv1 1.0’, combines an in silico prediction from Derek Nexus with results from two OECD-validated in chemico/in vitro assays (DPRA and h-CLAT) to provide hazard and potency skin sensitisation predictions, without the use of animal tests.
10 February 2022
Lhasa Limited is delighted to announce the release of Vitic 2022.1.
Over the past 12 months, a focus for Scientists at Lhasa Limited has been on developing genotoxicity and carcinogenicity endpoints in Vitic. Vitic aims to provide a wealth of high-quality data to support chemical risk assessments. Within this article, we explore some of the key improvements in the 2022.1 Vitic data release.
Lhasa Limited announces the release of Effiris 2.2 - providing accurate secondary pharmacology predictions for novel compounds
17 January 2022
Effiris delivers state-of-the-art secondary pharmacology models, where each model is able to learn from the private data of all pharmaceutical collaborators. As a result, Effiris overcomes one of the main challenges facing model development in drug discovery - accessing and utilising high-quality proprietary data.
Prior to this release, Effiris already offered model building – the ability to build teacher models in Effiris using in-house confidential data, privacy-preserving data sharing – the production of label files which extract knowledge while preserving all confidential aspects of the compounds used, and hybrid model building – collating Effiris member’s confidential dataset labels with the shared knowledge available in Effiris and publicly available data, in order to generate more comprehensive dataset to build a hybrid models.
What can you expect from Effiris 2.2?...
14 December 2021
Lhasa Limited releases new data to Nitrites in Excipients project users.
08 December 2021
Lhasa Limited releases new data into its Elemental Impurities Database
15 October 2021
07 October 2021
Supporting more scientifically driven nitrosamine risk assessments, we are pleased to announce the release of more data to our Nitrites in Excipients project users.
23 September 2021
New PDE data is released into the AI/PDE database.